



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date:9.2.2024

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
205(A), 2nd floor, Piramal Agastya Corporate Park,
Kamani Junction, LBS Road,
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 9th February, 2024 -- Reg.

Ref: Disclosure under Regulation 30 and 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 - Reg.

Pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., Friday, 9th February, 2024 had inter-alia transacted the following items of business:

- 1, Approved the Un-audited Financial Results along with the segment results for the quarter and nine months ended 31st December,2023.
2. Taken on record the Limited Review Report received from the statutory auditors of the company for the quarter and nine months ended 31st December, 2023.
3. Reconstituted the Nomination and Remuneration Committee of the Board of Directors and their composition is as under:-

Nomination and Remuneration Committee:

Name	Designation	Category
Sri. T. Govardhana Rao	Chairman	Independent Director
Smt. Shilpa Bung	Member	Independent Director
Ms. Sridevi Madati	Member	Independent Director
Sri. P.C. Sai Babu	Member	Non-Executive Director

We wish to inform that the company has not issued any Non-Convertible Debt Securities, Non-Convertible Redeemable Preference Shares (NCRPS) and Commercial Papers or any other instruments and as such the SEBI circular no. SEBI/HO/DDHS/DDHS/CIR/P/2020/231 dated November 13, 2020 is not applicable to the company.

LEKHA SAI Digitally signed by
SURAPANE LEKHA SAI
NI SURAPANENI
Date: 2024.02.09
17:05:58 +05'30'



SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

We herewith enclose the following:

- A. Un-Audited financial Results along with the segment results, for the quarter and nine months ended 31st December, 2023.
- B. Limited Review Report issued by Statutory Auditors for the quarter and nine months ended 31st December, 2023.

Kindly take the above on your records.

Thanking you,

Yours faithfully,
For Sigachi Laboratories Limited

LEKHA SAI
SURAPANENI

Digitally signed by
LEKHA SAI
SURAPANENI
Date: 2024.02.09
17:06:21 +05'30'

(S. Lekha Sai)
Company Secretary

The meeting Commenced at 4:00 PM
The Meeting Concluded at 5:00 PM

SIGACHI LABORATORIES LIMITED
 Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.
 Tel No.: 040 - 23204230 / 23204273
 Website: www.sillab.com, Email: sigachilaboratories@yahoo.co.in
 CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For The Quarter and Nine Months ended 31st December, 2023

(Rs.in lakhs)

Sl.No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	109.25	87.28	61.54	297.49	163.00	194.70
2	Other income	13.98	22.52	13.85	46.12	34.81	50.26
3	Total Income (1+2)	123.23	109.80	75.39	343.61	197.81	244.96
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Impairment on Advances	-	75.00	-	75.00	-	-
	d) Fair Value Loss	-	-	-	-	-	-
	e) Employee benefits expense	8.45	10.11	8.66	28.12	26.35	35.79
	f) Finance costs	-	-	-	-	-	-
	g) Depreciation and amortization expense	5.66	5.80	5.02	16.46	13.86	18.88
	h) Other expenses	3.79	3.22	3.00	11.20	10.57	17.05
	Total Expenses	17.90	94.13	16.68	130.78	50.78	71.72
5	Profit/(Loss) before exceptional items and tax (3-4)	105.33	15.67	58.71	212.83	147.03	173.24
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	105.33	15.67	58.71	212.83	147.03	173.24
8	Tax expense						
	(a) Current tax	9.96	11.13	12.35	27.54	31.25	46.45
	(b) Deferred tax	6.87	2.36	9.45	19.20	5.22	(4.21)
	Total Tax Expense	16.83	13.49	21.80	46.74	36.47	42.24
9	Profit/(Loss) for the Period (7-8)	88.50	2.18	36.91	166.09	110.56	131.00
10	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or loss	119.39	88.26	64.90	349.47	12.41	(31.97)
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.14
	Tax on Items that will not be reclassified to profit or loss	(16.08)	(9.18)	-	(40.01)	-	-
	(c) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	103.31	79.08	64.90	309.46	12.41	(31.83)
	Total Comprehensive income (9+10)	191.81	81.26	101.81	475.55	122.97	99.17
11	Paid-up Equity Share Capital (Face Value Rs.10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	-	-	2,342.90
13	Earnings per equity share (of Rs.10/- each) (not annualized (Rs.)						
	(1) Basic	1.31	0.03	0.55	2.46	1.64	1.94
	(2) Diluted	1.31	0.03	0.55	2.46	1.64	1.94

RAJASEKHA R
 TUNUGUNTLA
 LA

Digitally signed
 by RAJASEKHAR
 TUNUGUNTLA
 Date: 2024.02.09
 17:04:17 +05'30'

Segment wise Revenue, Results and Capital Employed for the Quarter and Nine Months ended 31st December, 2023

(Rs.in lakhs)

Sl.No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	33.50	33.00	32.00	88.50	84.50	128.50
	b) Investments	89.73	76.80	43.39	255.11	113.31	116.46
	Total	123.23	109.80	75.39	343.61	197.81	244.96
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net Sales/Income from Operations	123.23	109.80	75.39	343.61	197.81	244.96
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	27.66	27.02	26.80	71.23	69.82	107.69
	b) Investments	89.73	76.80	43.39	255.11	113.31	116.46
	Total	117.39	103.82	70.19	326.34	183.13	224.15
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	12.06	88.15	11.48	113.51	36.10	50.91
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	105.33	15.67	58.71	212.83	147.03	173.24
3	Capital Employed						
	(Segment Assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	785.90	899.22	729.13	785.90	729.13	894.97
	b) Investments	2,763.61	2,458.48	2,368.63	2,763.61	2,368.63	2,178.99
	Total	3,549.51	3,357.70	3,097.76	3,549.51	3,097.76	3,073.96

Notes :

- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.
- The above unaudited results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their respective meeting(s) held on 09th February, 2024.
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- These Financial Results are available on the Stock Exchange website (www.mseil.in) and also on the company's website at (www.sllab.com).
- Figures for the previous periods have been rearranged/reclassified wherever necessary to conform to the current period presentation.

for SIGACHI LABORATORIES LIMITED

RAJASEKHAR
TUNUGUNTLA
Date: 2024.02.09 17:05:03
+05'30'

(T.R.Sekhar)
Executive Director
DIN:02943146

Place : Hyderabad
Date : 09.02.2024



Limited Review Report on Unaudited financial results of M/s Sigachi Laboratories Limited

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s Sigachi Laboratories Limited pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF Sigachi Laboratories Limited

We have reviewed the accompanying unaudited financial results of **M/s Sigachi Laboratories Limited**, for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Sigachi Laboratories Limited** as at 31 December 2023.

For NSVR & Associates LLP
Chartered Accountants
FRN: 008801S/S2000060

V. G. Chaitanya

V Gangadhara Rao
Partner

M. No.219486

UDIN: 24219486BKFAXB5491

Place: Hyderabad

Date: 09-02-2024.



MSEI LTD
ACKNOWLEDGEMENT

Acknowledgement No	: 0902202405254533	Date & Time	: 09/02/2024 05:25:45 PM
Symbol	: SIGACHI		
Entity Name	: SIGACHI LABORATORIES LIMITED		
Compliance Type	: Regulation 33 - Financial Results		
Quarter / Period	: 31/12/2023		
Mode	: E-Filing		

General information about company	
Scrip code	000000
NSE Symbol	
MSEI Symbol	SIGACHI
ISIN*	INE368H01018
Name of company	SIGACHI LABORATORIES LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Date of board meeting when results were approved	09-02-2024
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	31-01-2024
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Multi segment
Description of single segment	
Start date and time of board meeting	09-02-2024 04:00
End date and time of board meeting	09-02-2024 05:00
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2023	01-04-2023
B	Date of end of reporting period	31-12-2023	31-12-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	109.246	297.49
	Other income	13.981	46.123
	Total income	123.227	343.613
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	8.448	28.122
(e)	Finance costs	0	0
(f)	Depreciation, depletion and amortisation expense	5.66	16.461
(f)	Other Expenses		
1	IMPAIRMENT ON ADVANCE	0	75
2	MISCELLANEOUS EXPENSES	0.833	2.162
3	RENT	0.42	1.35
4	CONVEYANCE EXPENSES	0.31	1.022
5	PROFESSIONAL CHARGES	0.796	1.016
6	INSURANCE	0	0.872
7	LOSS ON REDEMPTION OF BONDS	0.792	0.792
8	OFFICE MAINTENANCE	0.228	0.583
9	FACTORY MAINTENANCE	0.18	0.54
10	OTHER EXPENSES	0.231	2.86
	Total other expenses	3.79	86.197
	Total expenses	17.898	130.78

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2023	01-04-2023
B	Date of end of reporting period	31-12-2023	31-12-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	105.329	212.833
4	Exceptional items	0	0
5	Total profit before tax	105.329	212.833
7	Tax expense		
8	Current tax	9.954	27.541
9	Deferred tax	6.871	19.199
10	Total tax expenses	16.825	46.74
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	88.504	166.093
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	88.504	166.093

Financial Results – Ind-AS			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2023	01-04-2023
B	Date of end of reporting period	31-12-2023	31-12-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Other comprehensive income [Abstract]			
1 Amount of items that will not be reclassified to profit and loss			
1	Items that will not be reclassified to profit or (loss)	119.387	349.466
	Total Amount of items that will not be reclassified to profit and loss	119.387	349.466
2	Income tax relating to items that will not be reclassified to profit or loss	16.082	40.011
3 Amount of items that will be reclassified to profit and loss			
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	103.305	309.455

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2023	01-04-2023
B	Date of end of reporting period	31-12-2023	31-12-2023
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	191.809	475.548
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	675.31	675.31
	Face value of equity share capital	10	10
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	1.311	2.46
	Diluted earnings (loss) per share from continuing operations	1.311	2.46
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	1.311	2.46
	Diluted earnings (loss) per share from continuing and discontinued operations	1.311	2.46
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block	
Textual Information(1)	<ol style="list-style-type: none">1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016.2.The above unaudited results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their respective meeting(s) held on 09th February, 2024.3.The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.4.These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.slllab.com).5.Figures for the previous periods have been rearranged/reclassified wherever necessary to conform to the current period presentation.

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results			
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-10-2023	01-04-2023
Date of end of reporting period		31-12-2023	31-12-2023
Whether accounts are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)		
	(net sale/income from each segment should be disclosed)		
1	Bulk Drugs and Intermediates (Lease Rents)	33.5	88.501
2	Investments	89.727	255.112
	Total Segment Revenue	123.227	343.613
	Less: Inter segment revenue	0	0
	Revenue from operations	123.227	343.613
2	Segment Result		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	Bulk Drugs and Intermediates (Lease Rents)	27.659	71.233
2	Investments	89.727	255.112
	Total Profit before tax	117.386	326.345
	i. Finance cost	0	0
	ii. Other Unallocable Expenditure net off Unallocable income	12.057	113.512
	Profit before tax	105.329	212.833
3	(Segment Asset - Segment Liabilities)		
	Segment Asset		
1	Bulk Drugs and Intermediates (Lease Rents)	948.437	948.437
2	Investments	2763.612	2763.612
	Total Segment Asset	3712.049	3712.049
	Un-allocable Assets	0	0
	Net Segment Asset	3712.049	3712.049
4	Segment Liabilities		
	Segment Liabilities		
1	Bulk Drugs and Intermediates (Lease Rents)	162.539	162.539
2	Investments	0	0
	Total Segment Liabilities	162.539	162.539
	Un-allocable Liabilities		
	Net Segment Liabilities	162.539	162.539
	Disclosure of notes on segments		

